Skip to Content


In the US, Sutent (sunitinib systemic) is a member of the following drug classes: multikinase inhibitors, VEGF/VEGFR inhibitors and is used to treat Gastrointestinal Stromal Tumor, Pancreatic Cancer and Renal Cell Carcinoma.

US matches:

UK matches:

Ingredient matches for Sutent


Sunitinib is reported as an ingredient of Sutent in the following countries:

  • Bosnia & Herzegowina
  • Egypt
  • Georgia
  • Lebanon
  • Norway
  • Poland
  • Spain
  • Taiwan
  • Tunisia
  • Turkey

Sunitinib malate (a derivative of Sunitinib) is reported as an ingredient of Sutent in the following countries:

  • Argentina
  • Australia
  • Austria
  • Belgium
  • Canada
  • China
  • Croatia (Hrvatska)
  • Czech Republic
  • Denmark
  • Ecuador
  • Finland
  • France
  • Germany
  • Greece
  • Hong Kong
  • Hungary
  • Iceland
  • Indonesia
  • Ireland
  • Israel
  • Italy
  • Japan
  • Latvia
  • Lithuania
  • Malaysia
  • Netherlands
  • New Zealand
  • Philippines
  • Portugal
  • Romania
  • Serbia
  • Singapore
  • Slovakia
  • South Africa
  • Sweden
  • Switzerland
  • Thailand
  • United Kingdom
  • United States
  • Vietnam

Important Notice: The international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.